Browsing by Subject "Alzheimer’s disease"
Now showing items 1-10 of 15
-
1,3,7-Triethyl-substituted xanthines-possess nanomolar affinity for the adenosine A1 receptor
(Elsevier, 2015)Adenosine A1 receptors are attracting great interest as drug targets for their role in cognitive deficits. Antagonism of the adenosine A1 receptor may offer therapeutic benefits in complex neurological diseases, such as ... -
2-Benzylidene-1-indanone analogues as dual adenosine A1/A2a receptor antagonists for the potential treatment of neurological conditions
(Thieme, 2019)Previous studies explored 2-benzylidine-1-tetralone derivatives as innovative adenosine A1 and A2A receptor antagonists for alternative non-dopaminergic treatment of Parkinson’s disease. This study’s aim is to investigate ... -
4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis
(Taylor & Francis, 2019)A new series of 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivatives were designed, synthesised, and evaluated to assess their inhibitory effect on the human monoamine oxidase (hMAO) A and B isoforms. Different (un)substituted ... -
5-Substituted 2-benzylidene-1-tetralone analogues as A1 and/or A2A antagonists for the potential treatment of neurological conditions
(Elsevier, 2017)Adenosine A1 and A2A receptors are attracting great interest as drug targets for their role in cognitive and motor deficits, respectively. Antagonism of both these adenosine receptors may offer therapeutic benefits in ... -
The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues
(Elsevier, 2015)Based on a report that sulfanylphthalimides are highly potent monoamine oxidase (MAO) B selective inhibitors, the present study examines the adenosine receptor affinities and MAO-B inhibitory properties of a series of 4- ... -
Evaluation of selected dye compounds as inhibitors of enzymes, relevant to neurological disorders
(North-West University (South-Africa), 2021)Neurological disorders such as Alzheimer’s disease, Parkinson’s disease and schizophrenia are disorders that affect a large part of the population, especially the elderly. The cause of these disorders is still not completely ... -
Evaluation of selected dye compounds as inhibitors of monoamine oxidase
(North-West University (South-Africa), 2019)Parkinson’s disease (PD) and Alzheimer’s disease (AD) are neurodegenerative diseases that significantly impact the quality of life of patients. The pathology of Parkinson’s disease is characterised by neuronal death of the ... -
Imidazo[1,2-α]pyridines possess adenosine A1 receptor affinity for the potential treatment of cognition in neurological disorders
(Elsevier, 2017)Previous research has shown that bicyclic 6:5-fused heteroaromatic compounds with two N-atoms have variable degrees of adenosine A1 receptor antagonistic activity. Prompted by this imidazo[1,2-α]pyridine analogues were ... -
MAO inhibitors and their wider applications: a patent review
(Taylor & Francis, 2018)Introduction: Monoamine oxidase (MAO) inhibitors, after the initial ‘golden age’, are currently used as third-line antidepressants (selective MAO-A inhibitors) or clinically enrolled as co-adjuvants for neurodegenerative ... -
Multi-targeted directed ligands for Alzheimer’s disease: design of novel lead coumarin conjugates
(Taylor & Francis, 2018)Alzheimer’s Disease (AD) is a neurodegenerative disease characterized by central nervous system insults with progressive cognitive (memory, attention) and non-cognitive (anxiety, depression) impairments. Pathophysiological ...